Stryker (NYSE:SYK) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report issued on Tuesday, January 2nd, Marketbeat.com reports.
SYK has been the topic of a number of other research reports. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $161.00 to $173.00 in a research report on Thursday, November 16th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a report on Friday, November 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $156.00 price target on shares of Stryker in a report on Friday, October 27th. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. Stryker has a consensus rating of “Hold” and an average price target of $156.60.
Stryker (NYSE SYK) traded down $0.94 during trading on Tuesday, reaching $158.60. 1,129,590 shares of the company were exchanged, compared to its average volume of 1,215,836. The stock has a market capitalization of $59,350.00, a P/E ratio of 33.82, a price-to-earnings-growth ratio of 2.30 and a beta of 0.78. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. Stryker has a 52 week low of $119.17 and a 52 week high of $164.20.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the previous year, the business posted $1.39 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. sell-side analysts anticipate that Stryker will post 6.47 EPS for the current year.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in SYK. Acrospire Investment Management LLC purchased a new position in shares of Stryker in the 2nd quarter valued at approximately $111,000. Motco increased its holdings in Stryker by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares during the period. Sawyer & Company Inc acquired a new position in Stryker in the 4th quarter worth approximately $125,000. Sit Investment Associates Inc. increased its holdings in Stryker by 114.3% in the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after buying an additional 440 shares during the period. Finally, San Francisco Sentry Investment Group CA increased its holdings in Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after buying an additional 325 shares during the period. 74.90% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Stryker (SYK) Upgraded to “Overweight” by JPMorgan Chase & Co.” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/11/jpmorgan-chase-co-upgrades-stryker-syk-to-overweight.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.